Muscle Anabolism
4
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
MSDIreland - Ballydine
2 programs2
Comparator: Testosterone 300 mg, intramuscular injectionPhase 11 trial
Comparator: low dose testosteronePhase 11 trial
Active Trials
Sharp TherapeuticsPA - Pittsburgh
2 programs2
Comparator: Testosterone 300 mg, intramuscular injectionPhase 1
Comparator: low dose testosteronePhase 1
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MSDComparator: Testosterone 300 mg, intramuscular injection
MSDComparator: low dose testosterone
Clinical Trials (2)
Total enrollment: 58 patients across 2 trials
A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064)
Start: Jan 2008Est. completion: Dec 200828 patients
Phase 1Completed
Biomarkers of Muscle Anabolism (MK-0000-082)
Start: Nov 2007Est. completion: Feb 200830 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.